CABALETTA BIO, INC. Increase (Decrease) in Interest Payable, Net
CABALETTA BIO, INC. (CABA) reported Increase (Decrease) in Interest Payable, Net of -$221.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2026-08-13
- CABALETTA BIO, INC. increase (decrease) in interest payable, net for the quarter ending 2026-06-30 was $20.00K, a 42.86% increase year-over-year.
- CABALETTA BIO, INC. increase (decrease) in interest payable, net for the quarter ending 2026-03-31 was -$241.00K, a 380.23% decline year-over-year.
- CABALETTA BIO, INC. increase (decrease) in interest payable, net for the quarter ending 2025-06-30 was $14.00K.
- CABALETTA BIO, INC. increase (decrease) in interest payable, net for the quarter ending 2025-03-31 was $86.00K.
- CABALETTA BIO, INC. increase (decrease) in interest payable, net for fiscal 2025 was $291.00K.
- CABALETTA BIO, INC. increase (decrease) in interest payable, net for fiscal 2024 was $0.00.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|
| 2026-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$221.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$241.00K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $291.00K 10-K · filed 2026-03-23 | ||
| 2025-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $100.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $86.00K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |